Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jaguar Health, Inc.JAGX · Entity 8387 | See Remarks | December 11, 2025 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jaguar Health, Inc.
Report date December 11, 2025 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,885 |
Reported balance
After 2025-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 11,740 · Balance 11,885 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2035-12-11 | Direct | 11,740 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Grant · Acquired 11,740 · Balance 11,740 F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F4: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
F4: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Jan 21, 2026 21:30 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 11,740 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001193125-26-018044 · ownership.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,740 Underlying: Common Stock · 11,740 shares Expires 2035-12-11 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F4 · derivative.exercise_date: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| December 11, 2025 Filed Jan 21, 2026 21:30 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 11,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-018044 · ownership.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,885 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:36 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantWarrant to Purchase Common Stock · Derivative | 7,304 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0000950170-25-090445 · ownership.xml · derivative · entry 3 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 7,304 shares Expires 2026-12-24 F2 · price: As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 7,304 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. F2 · derivative.exercise_date: As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 7,304 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:36 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantConvertible Promissory Note · Derivative | 3,785 | $20.00 Strike: $5.56 | $75,700.00 |
DisclosureSEC source: 0000950170-25-090445 · ownership.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,785 Underlying: Common Stock · 3,785 shares Expires not disclosed F1 · price: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.exercise_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.expiration_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:36 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Disposition to issuerConvertible Promissory Note · Derivative | 3,600 | $20,000.00 Strike: $5.56 | $72,000,000.00 |
DisclosureSEC source: 0000950170-25-090445 · ownership.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · price: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.exercise_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.expiration_date: The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,785 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. Read SEC document |
| May 17, 2025 Filed May 20, 2025 21:05 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075339 · ownership.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "May 2024 Reverse Stock Split). Upon effectiveness of the May 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 18, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "March 2025 Reverse Stock Split"). F3 · derivative.exercise_price: (Continued from footnote 2) Upon effectiveness of the March 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. F4 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split, the May 2024 Reverse Stock Split and the March 2025 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F4 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split, the May 2024 Reverse Stock Split and the March 2025 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 17, 2025 Filed May 20, 2025 21:05 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-075339 · ownership.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "May 2024 Reverse Stock Split). Upon effectiveness of the May 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 18, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "March 2025 Reverse Stock Split"). F3 · balance_after: (Continued from footnote 2) Upon effectiveness of the March 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:10 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | PurchaseWarrant to Purchase Common Stock · Derivative | 3,600 | Not disclosed Strike: $5.43 | Not disclosed |
DisclosureSEC source: 0000950170-25-049808 · ownership.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2030-03-31 F2 · price: As an inducement to enter into the Purchase Agreement, the reporting person received a warrant (the "Warrant") to purchase up to 3,600 shares of Common Stock with an exercise price of $5.43 per share. The Warrant is exercisable immediately upon issuance and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. Read SEC document |
| March 31, 2025 Filed Apr 3, 2025 00:10 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | PurchaseConvertible Promissory Note · Derivative | 3,600 | $20,000.00 Strike: $5.56 | $72,000,000.00 |
DisclosureSEC source: 0000950170-25-049808 · ownership.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,600 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. F1 · derivative.expiration_date: The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 3,600 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 01:53 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 39,376 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-24-114181 · ownership.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,376 Underlying: Common Stock · 39,376 shares Expires 2034-10-08 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024. F5 · derivative.exercise_date: The options will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| October 08, 2024 Filed Oct 11, 2024 01:53 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 4,922 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-114181 · ownership.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,951 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on October 8, 2024. F3 · date: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest in three equal annual installments beginning on October 8, 2025. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. F4 · balance_after: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the " Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:01 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 612 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063895 · tm2414996-5_4seq1.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612 Underlying: Common Stock · 612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:01 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-063895 · tm2414996-5_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| April 05, 2024 Filed Apr 17, 2024 20:31 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048341 · tm2411853-5_4seq1.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 178 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2024 Filed Apr 17, 2024 20:31 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-048341 · tm2411853-5_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 20:46 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantCommon Stock | 159,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-091448 · tm2320633-1_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · see remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,133 Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:01 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-062742 · tm2316214-8_4seq1.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,224 Underlying: Common Stock · 611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F3 · derivative.expiration_date: The restricted stock units were originally approved by the issuer's board of directors on March 28, 2022 and previously reported as covering 137,685 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:01 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-062742 · tm2316214-8_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| April 05, 2023 Filed Apr 20, 2023 21:17 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 177 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-047876 · tm2311973-2_4seq1.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177 Underlying: Common Stock · 177 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the September 2021 Reverse Stock Split and January 2023 Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2023 Filed Apr 20, 2023 21:17 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 177 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-047876 · tm2311973-2_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 02:09 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 42,223 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001104659-22-130630 · tm2233639-5_4seq1.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,223 shares Expires 2031-04-05 F2 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. F1 · balance_after: The option was cancelled by mutual agreement of the reporting person and Jaguar Health, Inc. The reporting person received $300 as consideration for the cancellation. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 13,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-043243 · tm2211739-5_4seq1.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,666 Underlying: Common Stock · 13,333 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 120,000 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on April 5, 2021 and vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-043243 · tm2211739-5_4seq1.xml · nonDerivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:28 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 137,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-040393 · tm2210715-9_4seq1.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,685 Underlying: Common Stock · 137,685 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · date: The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:19 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-047560 · a4.xml · derivative · entry 2 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021. F5 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. F5 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date or dates provided in the grant notice. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:19 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001104659-21-047560 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Chief of Sustainable Supply 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2031-04-05 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021. F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 01:51 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 79,431 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-20-037936 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,431 Underlying: Common Stock · 79,431 shares Expires 2030-03-20 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on March 20, 2020. F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 20:50 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 347,351 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001104659-19-042085 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,351 Underlying: Common Stock · 347,351 shares Expires 2022-07-24 F1 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019. F3 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with five months of options, or 48,243 options, vested as of the grant date based on the reporting person's number of years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| June 01, 2018 Filed Jun 7, 2018 01:29 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 149,311 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001104659-18-038711 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,311 Underlying: Common Stock · 149,311 shares Expires 2028-04-12 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · security: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018. F3 · date: The option grant was approved by the Issuer's board of directors on April 12, 2018, subject to the stockholders approving and effecting a reverse stock split. The Issuer's shareholders approved the reverse stock split on May 18, 2018 and effected such stock split on June 1, 2018. F4 · derivative.exercise_date: Vests in equal monthly installments, beginning on May 1, 2018, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:32 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 1,327,881 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001104659-18-017524 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327,881 Underlying: Common Stock · 1,327,881 shares Expires 2027-08-02 F1 · security: Granted pursuant to the Issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the Issuer's board of directors on August 2, 2017, subject to shareholder approval of the amendment to the 2014 Stock Incentive Plan. The Issuer's shareholders approved the amendment on March 12, 2018. F3 · derivative.exercise_date: Vests in equal monthly installments, beginning August 2, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| December 21, 2017 Filed Dec 29, 2017 22:25 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 95,269 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001104659-17-075720 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,269 Underlying: Common Stock · 95,269 shares Expires 2027-12-21 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in full on March 31, 2018 if reporting person is an employee as of such date. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 19:35 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 4,496 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-16-163178 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,496 Underlying: Common Stock · 4,496 shares Expires 2026-12-19 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 16:00 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 23,042 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001104659-16-146472 · a4.xml · derivative · entry 1 King Steven R. · CIK 0001622052 · Executive VP and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,042 Underlying: Common Stock · 23,042 shares Expires 2026-09-22 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on October 22, 2016, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.